Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...
A multicentre clinical trial led by a researcher from the University of Sherbrooke will test a new therapeutic approach to moderate asthma. The study will include 150 patients, including 50 in Quebec, ...
GlobalData on MSN
GSK obtains FDA approval for Exdensur in severe asthma
Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.
Patients with chronic spontaneous urticaria (CSU) often experience impaired QOL, especially when antihistamines, the standard ...
We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...
ADRs, or American Depository Receipts, are the US-listed securities of foreign firms that allow investors in America to buy ...
Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...
New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...
TipRanks on MSN
Sanofi’s dupilumab study completion: Implications for asthma treatment and market impact
Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi recently completed a study titled ‘National, Multicenter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback